T. A. Zelniker, S. D. Wiviott, I. Raz, K. Im, E. L. Goodrich et al., SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, The Lancet, vol.393, issue.10166, pp.31-39, 2019.

J. Butler, Y. Handelsman, G. Bakris, and S. Verma, Use of sodium?glucose co?transporter?2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure, European Journal of Heart Failure, vol.22, issue.4, pp.604-617, 2020.

B. L. Neuen, T. Young, H. J. Heerspink, B. Neal, V. Perkovic et al., SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis, The Lancet Diabetes & Endocrinology, vol.7, issue.11, pp.845-854, 2019.

M. Packer, SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action, Diabetes Care, vol.43, issue.3, pp.508-511, 2020.

J. J. Mcmurray, S. D. Solomon, S. E. Inzucchi, L. Køber, M. N. Kosiborod et al., Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction, New England Journal of Medicine, vol.381, issue.21, pp.1995-2008, 2019.

. Dapa-hf, Correction to: Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF, Circulation, vol.142, issue.20, pp.1995-2008, 2020.

M. C. Petrie, S. Verma, K. F. Docherty, S. E. Inzucchi, I. Anand et al., Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes, JAMA, vol.323, issue.14, p.1353, 2020.

M. Packer, J. Butler, G. S. Filippatos, W. Jamal, A. Salsali et al., Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial, Eur J Heart Fail, vol.21, pp.1270-1278, 2019.

M. Packer, S. D. Anker, J. Butler, G. Filippatos, S. J. Pocock et al., Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure, New England Journal of Medicine, vol.383, issue.15, pp.1413-1424, 2020.
URL : https://hal.archives-ouvertes.fr/hal-03014260

L. , S. Sd, C. B. Granger, S. Yusuf, M. A. Pfeffer et al., CHARM Investigators and Committees. Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes, Cardiovasc Drugs Ther, vol.31, pp.545-549, 2017.

S. L. Kristensen, D. Preiss, P. S. Jhund, I. Squire, J. S. Cardoso et al., Risk Related to Pre?Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction, Circulation: Heart Failure, vol.9, issue.1, p.2560, 2016.

R. M. Witteles and M. B. Fowler, Insulin-Resistant Cardiomyopathy, Journal of the American College of Cardiology, vol.51, issue.2, pp.93-102, 2008.

C. D. Yang, Y. Shen, L. Lu, F. H. Ding, Z. K. Yang et al., Insulin resistance and dysglycemia are associated with left ventricular remodeling after myocardial infarction in non-diabetic patients, Cardiovascular Diabetology, vol.18, issue.1, p.100, 2019.

N. Uriel, Y. Naka, P. C. Colombo, M. Farr, S. W. Pak et al., Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices, European Journal of Heart Failure, vol.13, issue.2, pp.195-199, 2011.

H. Kim, S. Park, S. H. Kwon, J. S. Jeon, D. C. Han et al., Impaired fasting glucose and development of chronic kidney disease in non-diabetic population: a Mendelian randomization study, BMJ Open Diabetes Res Care, vol.8, p.1395, 2020.

N. Rathi, P. K. Whelton, G. M. Chertow, W. C. Cushman, A. K. Cheung et al., Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events, American Journal of Hypertension, vol.32, issue.12, pp.1170-1177, 2019.